Osilodrostat
Treatment for Cushings Syndrome
Typical Dosage: 2-30 mg twice daily
Effectiveness
55%
Safety Score
55%
Clinical Trials
9
Participants
400
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
55
DangerousModerateSafe
Treatment Details
Dosage Range
2-30 mg twice daily
Time to Effect
2-4 weeks
Treatment Duration
lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
2.5(Treat 2.5 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
3.5(Treat 3.5 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$140,000
Monitoring:$2,000
Side Effect Mgmt:$1,500
Total Annual:$143,500
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$580,000/QALY
QALYs Gained
0.5
Outcome-Based Costs
Cost per Responder
$260,909
Cost per Remission
$260,909
Active Clinical Trials
7 active trials recruiting for Osilodrostat in Cushings Syndrome
Non-interventional Study on Osilodrostat in Patients With Endogenous Cushing's Syndrome
NCT05382156ACTIVE NOT RECRUITING
206 participants
OBSERVATIONAL
Phoenix, United States +42 more
Started: Jun 13, 2022
A Block-and-Replace Therapy With Osilodrostat and Concomitant Glucocorticoid Replacement
NCT06430528RECRUITING
12 participants
OBSERVATIONAL
Ann Arbor, United States
Started: Jul 19, 2024
Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Syndrome
NCT03708900RECRUITINGPHASE2
12 participants
INTERVENTIONAL
San Francisco, United States +11 more
Started: Apr 28, 2021
Osilodrostat in Patients With Hypertension Caused by Hypercortisolaemia Due to Cushing's Syndrome
NCT07247162NOT YET RECRUITINGPHASE4
63 participants
INTERVENTIONAL
Started: Aug 1, 2026
Impact of 1 mg Osilodrostat Therapy on Mild Autonomous Cortisol Secretion (MACS)
NCT07104812NOT YET RECRUITINGPHASE2
15 participants
INTERVENTIONAL
Rochester, United States
Started: Jan 1, 2026
Osilodrostat Therapy and 11C-methionine PET to Improve Corticotroph Adenoma Detection
NCT06701838NOT YET RECRUITING
15 participants
OBSERVATIONAL
Started: Dec 3, 2024
Isturisa Treatment in Mild Autonomous Cortisol Secretion( MACS)
NCT07247058RECRUITINGPHASE4
10 participants
INTERVENTIONAL
Baltimore, United States
Started: Jan 20, 2026
Completed Clinical Trials
3 completed trials for Osilodrostat in Cushings Syndrome
Osilodrostat for the Treatment of Non-Cushing's Disease Cushing's Syndrome
NCT05633953COMPLETED
103 participants
OBSERVATIONAL
Pessac, France
Started: Jan 16, 2023
Roll-over Study in Patients With Endogenous Cushing's Syndrome for LCI699
NCT03606408COMPLETEDPHASE2
127 participants
INTERVENTIONAL
Aurora, United States +55 more
Started: Oct 5, 2018
Study of Efficacy and Safety of Osilodrostat in Cushing's Syndrome
NCT02468193COMPLETEDPHASE2
9 participants
INTERVENTIONAL
Fukushima, Japan +3 more
Started: Sep 24, 2015